GENE ONLINE|News &
Opinion
Blog

AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan

by Joy Lin
Share To
Japan has granted marketing approvals to AstraZeneca’s Kosulego (selumetinib) and Tezspire (tezepelumab), treatments for plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) and severe asthma respectively. 

The approval of Kosulego, given by the Japanese Ministry of Health, Labor and Welfare (MHLW), makes it the first and only approved treatment for the treatment of children aged 3 years and older with PNs in NF1, a rare genetic condition that affects nerve tissue. Kosulego won US FDA approval for PNs in NF1 in April 2020, which was followed by a nod from the EU in June 2021. The drug is being developed as part of a massive $8.5 billion partnership between AstraZeneca and Merck (known outside the US and Canada as MSD). 

GO Prime with only $1.49 now

LATEST
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scientists Identified Potential New Drugs to Combat Blindness
2023-05-21
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
EVENT
2023-05-16
The 2nd International Healthcare Week
Hong Kong , China
2023-06-02
2023 ASCO annual meeting
Chicago, USA
2023-07-26
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023-09-06
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top